News >

Translating Trial Data to Treatment in Metastatic TNBC

Caroline Seymour
Published: Monday, May 06, 2019

Yuan Yuan, MD, PhD

Yuan Yuan, MD, PhD

Immunotherapy, PARP inhibitors, and antibody-drug conjugates (ADCs) have shown efficacy in patients with metastatic triple-negative breast cancer (TNBC), but enhanced genomic understanding and proper patient selection are necessary to determine the optimal use of these agents, explained Yuan Yuan, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x